Can Vitamin B3 (Nicotinamide) Really Reduce Skin Cancer Risk?
In this article
Nicotinamide, a Vitamin B3 Derivative: An Additional Layer of Skin Cancer Prevention
Skin cancer is more than a cosmetic concern; it is a serious group of diseases placing a growing burden on healthcare systems worldwide. In particular, sunlight-related keratinocyte cancers (basal cell carcinoma and cutaneous squamous cell carcinoma), or "nonmelanoma skin cancers," are among the most common cancers worldwide in prevalence.
The main preventive measures are avoiding sun exposure, wearing protective clothing, and regularly using sunscreen (SPF 30+) . In real life, however, adherence is not always adequate, creating a need for additional supportive strategies.
Nicotinamide (niacinamide), a vitamin B3 derivative, is an inexpensive, safe, readily accessible option. Research shows that nicotinamide both supports repair of UV-induced DNA damage and reduces immune suppression . This makes it stand out as a "pharmacological layer added to sun protection" against skin cancer.
Using the randomized controlled ONTRAC trial (NEJM, 2015) and real-world JAMA Dermatology (2025) analysis , we examine nicotinamide's efficacy, which patients should start it and when, and implications for the future.
Why Does It Matter?
- High burden: keratinocyte cancers impose substantial costs and workloads on healthcare systems.
- Prevention gap: sun protection and regular screening are essential, but adherence varies.
- Biological rationale: by supporting the NAD⁺ pool, nicotinamide prevents the fall in ATP after UV exposure, facilitates DNA repair and reduces UV-related immunosuppression in the skin.
- Clinical signal: in randomized controlled trials, nicotinamide reduced new skin cancer risk by 23%, compared with 14% in real-world data; when started immediately after the first skin cancer, the reduction may approach 54% in magnitude.
📊 Quick Numerical Summary
| Study | Participants | Treatment | Outcome |
|---|---|---|---|
| ONTRAC (NEJM 2015) |
386 high-risk patients Double-blind RCT |
Nicotinamide 500 mg 2 times daily for 12 months |
New skin cancers: 23% reduction; squamous cell cancer: 30% reduction; Actinic keratoses over 3–12 months: 11–20% reduction Effect disappears when the drug is stopped |
| VA Cohort (JAMA Derm. 2025) |
33,822 patients Retrospective, real-world |
Nicotinamide 500 mg 2 times daily for ≥30 days |
Overall risk: 14% reduction; If started after the first skin cancer: ~54% reduction; Greatest benefit in squamous cell cancer |
Note: this table briefly summarizes findings examined in detail below.
Main Message
Nicotinamide, particularly when used after the first skin cancer , is an inexpensive and safe supportive treatment. It does not replace sun protection, but alongside it may reduce new skin cancer risk. Its effect continues only while the drug is being taken ; benefit disappears after stopping. The most pronounced benefit is seen in squamous cell skin cancer patients.
Mechanism: How Does Nicotinamide Act Against UV Damage?
Nicotinamide (niacinamide), a precursor for NAD⁺ biosynthesis, is a vitamin B3 derivative. In UV-exposed epidermis, ATP consumption and NAD⁺ depletion accelerate, weakening DNA repair (particularly NER/BER) and the immune response . By supporting intracellular energy balance, nicotinamide supplementation increases DNA repair capacity and reduces UV-induced immunosuppression in the skin.
🧬 Four Biological Steps: 4-Part Overview
- UV Damage & Energy Loss: UVB creates photoproducts such as CPD and 6-4PP in DNA. Repair is energy-intensive; NAD⁺/ATP depletion disrupts repair.
- Supporting the NAD⁺ Pool: nicotinamide contributes to NAD⁺ synthesis; it buffers the energy collapseand facilitates DNA repair proteins (e.g., NER/BER components).
- DNA Repair & Genome Stability: damage accumulated after UV exposure is cleared faster, which may help reduce progression of premalignant lesions in the skin.
- Immune Effect: UV-triggered local immunosuppression (e.g., loss of Langerhans cell function, cytokine imbalance) is reduced; without substantially altering baseline immunity, UV-specific suppression is alleviated.
Note: clinical studies reported similar immune-protective effects over 500–1500 mg/day; the preferred RCT regimen is 500 mg twice dailyin practice.
🔧 Repair Pathways (Summary)
- NER: removal of bulky UV-specific lesions (CPD, 6-4PP) from DNA
- BER: repair of oxidative/minor base damage
- Energy requirements: both pathways integrate with NAD⁺/ATP -dependent processes
🛡️ Immune Modulation
- UV-triggered local immunosuppression is reduced
- Antigen presentation and epidermal defense are supported
- Baseline immunity: effects without broad changes
⚠️ A Common Confusion
Niacin ≠ Nicotinamide. Niacin (nicotinic acid) may cause flush (facial redness) through vasodilation. Nicotinamide does not have this effect, and chemoprevention data are based on the nicotinamide form.
🔍 Niacin and Nicotinamide: Clinical Differences
| Feature | Nicotinic Acid (Niacin) | Nicotinamide (Niacinamide) |
|---|---|---|
| Primary use | Lipid lowering (high dose) | Skin cancer chemoprevention and photobiology |
| Flush (redness) | Common | Absent |
| Chemoprevention evidence | No evidence for NMSC | ONTRAC RCT + real-world data |
| Clinical dose (example) | High doses for dyslipidemia, limited by adverse effects | 500 mg BID (study dose, 12 months) |
Dose–response: studies reported similar protection against UV immunosuppression over 500–1500 mg/day. Clinical RCT and cohort data base practical use on the 500 mg twice-daily regimen.
Details of the Clinical Evidence: ONTRAC RCT and 2025 Real-World Data
This section compares results from the randomized controlled ONTRAC trial and a large cohort analysis in the Veterans Affairs (VA) database . The numbers are critical for showing who benefits most and under which conditions effects persist.
🧪 ONTRAC (NEJM, 2015): Phase 3, Double-Blind RCT
- Design: n=386 high-risk adults; nicotinamide 500 mg BID vs placebo, 12 months of treatment + 6 months of follow-up.
- Primary endpoint: number of new NMSCs (BCC + cSCC).
- Secondary endpoints: numbers of new BCCs, new cSCCs, and actinic keratoses (AK) (months 3, 6, 9, 12).
| Endpoint | Effect (Nicotinamide vs Placebo) | Statistics | Note |
|---|---|---|---|
| Total NMSC | 23% reduction (adjusted) | 95% CI 4–38%; p=0.02 | Consistent effect over 12 months; fades after stopping the drug. |
| BCC | 20% reduction (favorable direction) | 95% CI −6–39; p=0.12 | Signal mainly in the superficial BCC subtype. |
| cSCC | 30% reduction | 95% CI 0–51%; p=0.05 | The most pronounced clinical benefit is here. |
| Actinic Keratoses | At months 3, 6, 9, 12, 11–20% reduction | All significant (p≤0.01) | Difference begins early (month 3). |
🔒 Safety
An adverse effect profile similar to placebo ; no flushing. Routine laboratory monitoring is not required.
⏳ Sustainability
During the 6 months after discontinuation, benefit is not maintained — continuity matters.
📈 JAMA Dermatology (2025): VA Real-World Cohort
- Population: n=33,822; nicotinamide 500 mg BID used for ≥30 days by 12,287 people, versus 21,479 nonusers (propensity score-matched analysis).
- Primary measure: time from baseline to the first new skin cancer diagnosis.
- Subgroups: timing of initiation (after the first skin cancer vs later), transplant recipients, etc.
| Analysis | Risk Reduction | Comment |
|---|---|---|
| Overall (all NMSC) | 14% reduction | Clinically meaningful in the real world, but more modest than the RCT. |
| Timing of initiation: after the first skin cancer | ~54% reduction | Starting early provides greater benefit. |
| Subtype: cSCC | Strongest reduction | Consistent with clinical observations (also pronounced in ONTRAC). |
| Organ transplant recipients | Overall, not significant | Signal of reduced cSCC with early initiation; however, routine prophylaxis is not recommended. |
💡 Interpretation — Why the Difference?
The RCT had a selected high-risk population and frequent dermatological follow-up; in real life, patient heterogeneity, adherence and UV-related behaviors matter. Nevertheless, the 14% overall reduction is clinically meaningful and supports the importance of timing of initiation for benefit.
🔎 For Whom, When, and How Much? — An Evidence-Based Framework
- Target group: immunocompetent adults with a history of NMSC (particularly after the first event).
- Dose: 500 mg twice daily (study dose).
- Duration: effects continue while it is taken ; after stopping, benefits disappear.
- Organ transplant recipients: do not recommend routinely; individualize and consider alternatives.
🚀 TL;DR
RCTs show nicotinamide reduces NMSC by 23%, particularly cSCC by ~30% ; real-world data show an overall risk reduction of 14% in practice. Early initiation markedly increases benefit (~54%). The effect persists while treatment continues.
Practical Flowchart: Who, When, and How?
Nicotinamide is not a treatment to start routinely in everyone. The most important lesson from clinical studies is that starting at the right time in the right patient provides the greatest benefit. The following pathway offers clinicians a practical framework.
🔄 Clinical Decision Pathway
1️⃣ Risk Classification
- History of NMSC (particularly after the first event)
- Multiple actinic keratoses
- High UV exposure (occupational / geographical)
2️⃣ Basic Prevention
- Broad-spectrum SPF 30+
- Protective clothing, hat, sunglasses
- Avoid peak UV hours
3️⃣ Nicotinamide Decision
- Consider particularly after the first NMSC event
- 500 mg BID (study dose)
- Effect continues while it is taken consistently
4️⃣ Monitoring and Special Situations
- Dermatological examinations should continue
- If the drug is stopped, benefit disappears
- In organ transplant recipients, not routinely recommended
✅ Clinical Message
Nicotinamide is not yet suitable for recommendation to the general population. However, it may provide substantial benefit in high-risk, immunocompetent individuals especially when started after the first skin cancer diagnosis.
Special Populations, Safety, and Frequently Asked Questions
Although nicotinamide is considered safe for most patients, efficacy or applicability is limited in some special groups. These groups and common questions are summarized below.
👥 Special Populations
- Organ transplant recipients: ONTRANS Phase 3 (NEJM 2023) showed no benefit. Do not recommend routinely in this group; decide individually.
- Immunocompetent individuals: ONTRAC and the VA cohort provided the strongest data here. After the first NMSC, initiation provides the greatest benefit (~54% reduction).
- General population: currently, there is no recommendation for routine use. A risk-stratified approach is more appropriate.
🛡️ Safety Profile
- No flushing: do not confuse it with niacin (nicotinic acid); nicotinamide does not cause vasodilatory adverse effects.
- Dose tolerance: well tolerated in studies over 500–1500 mg/day.
- Adverse effect profile: similar to placebo in RCTs and cohorts; no significant laboratory abnormalities reported.
- Chronic use: continuity is needed to sustain effects; benefit disappears after stopping.
❓ Frequently Asked Questions
- How soon does it work?
- Actinic keratosis counts show a reduction from month 3 onward. The NMSC difference becomes clear at 12 months of treatment.
- Does the effect continue after stopping?
- No. In ONTRAC, within 6 months of stopping, the benefit disappeared. Continued use is essential.
- Does it replace sunscreen?
- No. Nicotinamide is an additional layer of protectionto consider alongside sunscreen and other measures.
- Can everyone use it?
- No. There is insufficient evidence to recommend it routinely to the general population. Decisions should be based on risk factors.
📌 Key Message
Nicotinamide, as a safe supplement, provides meaningful benefit particularly in immunocompetent individuals after their first NMSC . However, it is ineffective in organ transplant recipients, and not routinely recommended in the general population. Effects continue only while it is taken as treatment.
Looking Ahead: Future Research
Nicotinamide opened a new door in NMSC chemoprevention. Questions remain about the most effective patient groups, dose, and duration. Future research may move this field toward a more personalized, biomarker-based approach.
🔬 What Is on the Research Agenda?
- Timing: the VA cohort showed the greatest benefit when started after the first NMSC . However, optimal initiation timing and treatment duration remain unclear.
- Biomarkers: studies are investigating DNA repair capacity, NAD⁺ metabolism, and UV sensitivity as biomarkers to predict who will benefit.
- Dose optimization: RCTs used 500 mg BID, but the minimum effective and maximum tolerated dose still need definition.
- Special populations: reasons for failure in organ transplant recipients (profound immunosuppression, drug interactions) need clarification; new combination strategies (e.g., with immunomodulators) should be investigated.
- Real-world data: large cohorts from different regions with different UV exposure patterns are needed.
🌍 A Message for the Future
In coming years, nicotinamide may become part of personalized photoprotection strategies . Integrated with routine sunscreen use, it may find a wider place in dermatology as a low-cost, safe add-on agent in practice.
🚀 Clinical Vision
Nicotinamide has the potential, in NMSC prevention, to become the first pharmacological agent added to sun protection. The right patient, the right time, the right duration — as these become clearer, it will play a stronger role in dermatologists' preventive treatment arsenal.
References
- Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618–1626. doi: 10.1056/NEJMoa1506197
- Breglio KF, Knox KM, Hwang J, et al. Nicotinamide for Skin Cancer Chemoprevention. JAMA Dermatology. Published online September 17, 2025. doi: 10.1001/jamadermatol.2025.3238
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.